Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube
Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Levosulpiride and Movement Disorders–A Growing Concern
Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS
Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes
Objective: To review evidence on the risk of drug-induced movement disorders (DIMDs) with newer antipsychotic (AP) drugs. Background: DIMDs, both acute/subacute “extrapyramidal symptoms” and chronic…Trending the educational needs of US physicians related to managing patients with tardive dyskinesia
Objective: This study sought to understand evolving continuing medical education (CME) needs of US physicians managing patients with tardive dyskinesia (TD) by assessing the knowledge, practice, and barriers at three timepoints…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results
Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »